Related Experiment Video
Updated: Feb 4, 2026
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Renalase, Catecholamine and Nitric Oxide Changes Before and After Sodium Nitroprusside Administration to Patients who
1Cardiovascular Surgery Department, Elazig Research and Education Hospital, Health Science University, Elazig, Turkey.
Insights
Sodium nitroprusside (SNP) treatment for post-CABG hypertension increases renalase and nitric oxide (NO) levels while decreasing catecholamines. This suggests renalase preparations may effectively manage hypertension after coronary artery bypass grafting.
Area of Science:
- Cardiovascular Surgery
- Nephrology
- Pharmacology
Background:
- Hypertension affects 33-70% of patients post-Coronary Artery Bypass Grafting (CABG).
- Sodium nitroprusside (SNP) is a common antihypertensive agent.
- Renalase enzyme regulates blood pressure by degrading catecholamines.
Purpose of the Study:
- To investigate changes in renalase, catecholamines, and nitric oxide (NO) after SNP administration in post-CABG hypertension.
- To assess the impact of SNP on hemodynamic parameters in this patient group.
Main Methods:
- Study included 26 hypertensive post-CABG patients, 12 normotensive post-CABG patients, and 22 healthy controls.
- Renalase and catecholamine levels measured via ELISA; NO levels determined by spectrophotometry.
- Hemodynamic parameters (SAP, DAP, MAP, HR) monitored.
Main Results:
- Hypertensive post-CABG patients had lower renalase and NO, and higher catecholamines compared to controls.
- SNP administration increased renalase and NO levels, and decreased catecholamines.
- SNP reduced SAP, DAP, and MAP, with a slight heart rate increase.
Conclusions:
- SNP effectively increases renalase and NO, and reduces catecholamines in post-CABG hypertension.
- Renalase preparations combined with SNP may offer a novel therapeutic approach for managing post-CABG hypertension.
- This strategy targets catecholamine elevation, a key factor in post-CABG hypertension.
Background:
Hypertension develops at a rate of 33 to 70% after Coronary artery bypass grafting (CABG) operations. One of the most commonly used drugs to control hypertension is sodium nitroprusside (SNP). Additionally, renalase enzyme destroys catecholamines and mediates the regulation (reduction) of blood pressure. Thus, this clinical study aims to reveal how renalase, catecholamines and nitric oxide (NO) change and how certain hemodynamic parameters are affected in randomly and prospectively selected cases who are administered SNP for the treatment of blood pressure elevation within 6 to 8 hours after CABG surgery.
Methods:
The study included 26 patients who developed hypertension after CABG, 12 patients who had normal blood pressure after CABG, and 22 healthy individuals. Renalase and catecholamine levels of the patients were measured using ELISA method and NO levels were determined by spectrophotometry.
Results:
Renalase and NO levels of the patients who developed hypertension after CABG were found statistically significantly lower than those of healthy controls and patients who did not develop hypertension after CABG, while catecholamine levels were significantly higher in the former. After SNP was started, renalase and NO levels increased, and a significant decrease was observed in the catecholamine levels. Additionally, administration of SNP produced a slight increase in the heart rate and a decrease in systolic arterial pressure (SAP), diastolic arterial pressure (DAP) and means arterial pressure (MAP).
Conclusion:
SNP elevates NO and renalase levels; thus, administration of renalase preparations, which act in the destruction of catecholamines to contain persistent hypertension that develops in association with catecholamine elevation after CABG surgery, along with SNP and other medications used to lower blood pressure can be an effective therapeutic method to control hypertension.
More Related Videos
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:27Coronary Artery Disease V: Interprofessional Care
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Coronary Artery Disease III: Clinical Manifestations